Stifel Financial’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,663
| Closed | -$32K | – | 3560 |
|
|
2025
Q2 | $32K | Buy |
2,663
+1,067
| +67% | +$13.2K | ﹤0.01% | 3435 |
|
|
2025
Q1 | $22K | Hold |
1,596
| – | – | ﹤0.01% | 3388 |
|
|
2024
Q4 | $22.7K | Buy |
1,596
+66
| +4% | +$1.08K | ﹤0.01% | 3350 |
|
|
2024
Q3 | $29.1K | Sell |
1,530
-506
| -25% | -$8.64K | ﹤0.01% | 3328 |
|
|
2024
Q2 | $39.7K | Sell |
2,036
-567
| -22% | -$11K | ﹤0.01% | 3291 |
|
|
2024
Q1 | $59.7K | Buy |
2,603
+333
| +15% | +$7.18K | ﹤0.01% | 3247 |
|
|
2023
Q4 | $39.8K | Sell |
2,270
-1,300
| -36% | -$18.5K | ﹤0.01% | 3239 |
|
|
2023
Q3 | $46.6K | Sell |
3,570
-466
| -12% | -$7.06K | ﹤0.01% | 3187 |
|
|
2023
Q2 | $67.8K | Buy |
4,036
+3,187
| +375% | +$54.9K | ﹤0.01% | 3213 |
|
|
2023
Q1 | $13.2K | Buy |
849
+34
| +4% | +$660 | ﹤0.01% | 3303 |
|
|
2022
Q4 | $13.7K | Sell |
815
-100
| -11% | -$1.8K | ﹤0.01% | 3265 |
|
|
2022
Q3 | $16K | Sell |
915
-134
| -13% | -$2.94K | ﹤0.01% | 3244 |
|
|
2022
Q2 | $23K | Sell |
1,049
-116
| -10% | -$2.82K | ﹤0.01% | 3269 |
|
|
2022
Q1 | $40K | Sell |
1,165
-134
| -10% | -$4.01K | ﹤0.01% | 3321 |
|
|
2021
Q4 | $54K | Buy |
1,299
+290
| +29% | +$18.8K | ﹤0.01% | 3307 |
|
|
2021
Q3 | $91K | Buy |
1,009
+43
| +4% | +$3.79K | ﹤0.01% | 3250 |
|
|
2021
Q2 | $71K | Sell |
966
-284
| -23% | -$13.2K | ﹤0.01% | 3259 |
|
|
2021
Q1 | $46K | Buy |
1,250
+317
| +34% | +$15.9K | ﹤0.01% | 3163 |
|
|
2020
Q4 | $38K | Buy |
933
+3
| +0.3% | +$78 | ﹤0.01% | 2998 |
|
|
2020
Q3 | $21K | Sell |
930
-266
| -22% | -$6.87K | ﹤0.01% | 2848 |
|
|
2020
Q2 | $34K | Buy |
1,196
+329
| +38% | +$9.69K | ﹤0.01% | 2787 |
|
|
2020
Q1 | $23K | Hold |
867
| – | – | ﹤0.01% | 2719 |
|
|
2019
Q4 | $39K | Sell |
867
-200
| -19% | -$4.2K | ﹤0.01% | 2928 |
|
|
2019
Q3 | $12K | Hold |
1,067
| – | – | ﹤0.01% | 2838 |
|
|
2019
Q2 | $16K | Sell |
1,067
-692
| -39% | -$12.3K | ﹤0.01% | 2918 |
|
|
2019
Q1 | $37K | Buy |
1,759
+742
| +73% | +$14.7K | ﹤0.01% | 2755 |
|
|
2018
Q4 | $15K | Sell |
1,017
-180
| -15% | -$8.45K | ﹤0.01% | 2648 |
|
|
2018
Q3 | $108K | Sell |
1,197
-336
| -22% | -$39.9K | ﹤0.01% | 2668 |
|
|
2018
Q2 | $248K | Buy |
+1,533
| New | +$258K | ﹤0.01% | 2417 |
|
|
2017
Q1 | – | Sell |
-1,803
| Closed | -$242K | – | 2545 |
|
|
2016
Q4 | $242K | Buy |
+1,803
| New | +$453K | ﹤0.01% | 2167 |
|
Other funds holding CLSD
CG
AWM
GCP
Stifel Financial's CLSD Position: Q3 2025 in Review
Stifel Financial sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 2,663 shares — an estimated $32K sold.
Stifel Financial first reported a position in CLSD in Q4 2016 and held it in 30 quarters. The position peaked at $248K in Q2 2018. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.
- Stifel Financial reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
- Stifel Financial sold 2,663 Clearside Biomedical shares in Q3 2025, an estimated $32K.
- Stifel Financial first reported a position in Clearside Biomedical in Q4 2016 and held it in 30 quarters.
- Stifel Financial's Clearside Biomedical position peaked at $248K in Q2 2018.
- 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.
Based on Stifel Financial's 13F filing for Q3 2025, filed 12 Nov 2025.